CN103945865B - 用于将蛋白质递送至眼睛的缓释制剂及其制备方法 - Google Patents

用于将蛋白质递送至眼睛的缓释制剂及其制备方法 Download PDF

Info

Publication number
CN103945865B
CN103945865B CN201280028816.4A CN201280028816A CN103945865B CN 103945865 B CN103945865 B CN 103945865B CN 201280028816 A CN201280028816 A CN 201280028816A CN 103945865 B CN103945865 B CN 103945865B
Authority
CN
China
Prior art keywords
tocopherol
plga
alcohol
ester
atec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280028816.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103945865A (zh
Inventor
弗农·G·王
L·L·伍德
格伦·T·黄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramscor Inc
Icon Bioscience Inc
Original Assignee
Ramscor Inc
Icon Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramscor Inc, Icon Bioscience Inc filed Critical Ramscor Inc
Publication of CN103945865A publication Critical patent/CN103945865A/zh
Application granted granted Critical
Publication of CN103945865B publication Critical patent/CN103945865B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280028816.4A 2011-06-10 2012-06-11 用于将蛋白质递送至眼睛的缓释制剂及其制备方法 Active CN103945865B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495672P 2011-06-10 2011-06-10
US61/495,672 2011-06-10
PCT/US2012/041950 WO2013036309A2 (en) 2011-06-10 2012-06-11 Sustained release formulations for delivery of proteins to the eye and methods of preparing same

Publications (2)

Publication Number Publication Date
CN103945865A CN103945865A (zh) 2014-07-23
CN103945865B true CN103945865B (zh) 2016-10-26

Family

ID=47832748

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280028816.4A Active CN103945865B (zh) 2011-06-10 2012-06-11 用于将蛋白质递送至眼睛的缓释制剂及其制备方法

Country Status (22)

Country Link
US (1) US9814773B2 (https=)
EP (1) EP2717914B1 (https=)
JP (1) JP6339011B2 (https=)
KR (1) KR20140060274A (https=)
CN (1) CN103945865B (https=)
AU (1) AU2012304909B2 (https=)
BR (1) BR112013031685B1 (https=)
CA (1) CA2838289C (https=)
CY (1) CY1122771T1 (https=)
DK (1) DK2717914T3 (https=)
ES (1) ES2761340T3 (https=)
HR (1) HRP20192276T1 (https=)
HU (1) HUE047737T2 (https=)
IN (1) IN2013MN02384A (https=)
LT (1) LT2717914T (https=)
MX (1) MX359119B (https=)
PL (1) PL2717914T3 (https=)
PT (1) PT2717914T (https=)
RS (1) RS60051B1 (https=)
SI (1) SI2717914T1 (https=)
SM (1) SMT202000021T1 (https=)
WO (1) WO2013036309A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102245354B1 (ko) * 2013-05-24 2021-04-30 아이콘 바이오사이언스, 인크. 백내장 수술 후 염증에서의 서방출 덱사메타손의 용도
US11730716B2 (en) * 2014-05-08 2023-08-22 Kiora Pharmaceuticals Gmbh Compounds for treating ophthalmic diseases and disorders
US11090296B2 (en) * 2015-03-18 2021-08-17 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
CN107708738B (zh) * 2015-07-01 2022-03-25 参天制药株式会社 含有柠檬酸酯的贮库制剂
JP6949820B2 (ja) 2015-08-03 2021-10-13 トルマー インターナショナル リミテッド 薬物の持続投与のための液体ポリマー送達システム
EP3352735B1 (en) 2015-09-21 2023-08-30 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulations
WO2018172850A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
KR101957599B1 (ko) 2017-10-23 2019-03-13 김상현 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지
US11097061B2 (en) 2018-02-09 2021-08-24 Icon Bioscience, Inc. Systems, kits and methods for loading and delivering a small volume dose from a syringe
CA3097926A1 (en) 2018-05-01 2019-11-07 Chibi, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
EP4670713A1 (en) 2018-05-01 2025-12-31 Chibi, Inc. LIQUID DEPOSIT FOR THE PROLONGED NON-INVASIVE ADMINISTRATION OF AGENTS TO THE IL
JP2023526512A (ja) 2020-05-22 2023-06-21 トラスティーズ オブ ボストン ユニバーシティ 線維化疾患を処置するための方法および組成物
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
JP2024529009A (ja) 2021-07-06 2024-08-01 マーク・ヘースルトン セロトニン再取り込み阻害剤離脱症候群の治療

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CN1822816A (zh) * 2003-05-30 2006-08-23 阿尔萨公司 可植入的弹性体储库组合物、其用途以及制备方法
US7550441B2 (en) * 2003-06-06 2009-06-23 Massachusetts Institute Of Technology Controlled release polymer nanoparticle containing bound nucleic acid ligand for targeting
CN101588770A (zh) * 2006-12-01 2009-11-25 阿勒根公司 眼内药物递送系统

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658432B1 (fr) * 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
NZ523385A (en) * 2000-06-28 2005-09-30 Atul J Biodegradable vehicles and BAS-loaded delivery systems for use as biodegradable fillers and/or spacers, e.g. artificial skin
AR039729A1 (es) * 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
KR101341359B1 (ko) * 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
MX2007003789A (es) * 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2792484C (en) * 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
EP2269663B1 (en) * 2009-07-03 2018-03-07 Armbruster Biotechnology GmbH Bone graft and biocomposite

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CN1822816A (zh) * 2003-05-30 2006-08-23 阿尔萨公司 可植入的弹性体储库组合物、其用途以及制备方法
US7550441B2 (en) * 2003-06-06 2009-06-23 Massachusetts Institute Of Technology Controlled release polymer nanoparticle containing bound nucleic acid ligand for targeting
CN101588770A (zh) * 2006-12-01 2009-11-25 阿勒根公司 眼内药物递送系统

Also Published As

Publication number Publication date
JP6339011B2 (ja) 2018-06-06
US20140140992A1 (en) 2014-05-22
PT2717914T (pt) 2019-12-18
AU2012304909B2 (en) 2017-06-08
EP2717914A2 (en) 2014-04-16
NZ619707A (en) 2015-01-30
KR20140060274A (ko) 2014-05-19
SMT202000021T1 (it) 2020-03-13
WO2013036309A2 (en) 2013-03-14
HUE047737T2 (hu) 2020-05-28
ES2761340T3 (es) 2020-05-19
WO2013036309A3 (en) 2013-05-10
BR112013031685A2 (pt) 2017-02-07
IN2013MN02384A (https=) 2015-06-12
US9814773B2 (en) 2017-11-14
AU2012304909A1 (en) 2013-12-19
EP2717914A4 (en) 2015-05-13
CN103945865A (zh) 2014-07-23
MX2013014461A (es) 2014-05-14
MX359119B (es) 2018-09-14
HRP20192276T1 (hr) 2020-05-15
SI2717914T1 (sl) 2020-07-31
CA2838289C (en) 2019-09-10
BR112013031685B1 (pt) 2021-04-06
LT2717914T (lt) 2020-03-25
JP2014516087A (ja) 2014-07-07
CY1122771T1 (el) 2021-05-05
DK2717914T3 (da) 2020-01-20
RS60051B1 (sr) 2020-04-30
CA2838289A1 (en) 2013-03-14
EP2717914B1 (en) 2019-10-30
PL2717914T3 (pl) 2020-05-18

Similar Documents

Publication Publication Date Title
CN103945865B (zh) 用于将蛋白质递送至眼睛的缓释制剂及其制备方法
CN101060831B (zh) 可方便植入的缓释药物组合物
US20150037429A1 (en) Controlled Release Microparticles
JP2007535536A (ja) 高分子含有持続放出眼内インプラントおよび関連方法
US20200375889A1 (en) Bioerodible polyester polymer implants and related methods of use
JP2021521173A (ja) 眼内薬物送達用の持続放出微粒子のための方法及び組成物
US20200297651A1 (en) PPARa AGONIST COMPOSITIONS AND METHODS OF USE
NZ619707B2 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
HK1196081A (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
HK1196081B (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
Fan et al. Topical Gel/Microsphere Eyedrop for Combined Delivery of Brimonidine and Timolol: A Comparative Study With Traditional Eye Drops in Rabbits
Kimura et al. Biodegradable systems
US20190275001A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
TW201238609A (en) Conveniently implantable sustained release drug compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant